8-K: Inspire Medical Systems Announces Strong Preliminary 2024 Results and Initial 2025 Revenue Guidance

Inspire Medical Systems reports a 25% year-over-year revenue increase for Q4 2024 and provides initial 2025 revenue guidance of $940 million to $955 million.

Summary

• Inspire Medical Systems anticipates Q4 2024 revenue to be between $239.5 million and $239.7 million, a 25% increase year-over-year.
• Full-year 2024 revenue is expected to be in the range of $802.6 million to $802.8 million, representing a 28% increase compared to 2023.
• The company activated 72 new centers in the U.S. during Q4 2024, bringing the total to 1,435 U.S. medical centers implanting Inspire therapy.
• Inspire created 12 new sales territories in the U.S. in Q4 2024, bringing the total to 335 U.S. sales territories.
• The soft launch of the Inspire V neurostimulator has begun, with over 40 implants completed in Singapore and the U.S.
• Initial full-year 2025 revenue guidance is projected to be between $940 million and $955 million, a 17% to 19% increase over 2024.
• Jason Kelly has been appointed as the new Chief Manufacturing and Quality Officer, effective January 20, 2025.
• Carlton Weatherby will take on the expanded role of Chief Strategy and Growth Officer.
• Randy Ban will transition to the newly created role of EVP, Patient Access and Therapy Development.
• Ivan Lubogo will transition to the newly created role of SVP, Strategic Sales.
• Joe Sander will be promoted to the role of SVP U.S. Sales.
• Dr. Charisse Sparks, Chief Medical Officer, left Inspire at the beginning of the year.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook with strong revenue growth, new product launches, and strategic organizational changes. The sentiment is very optimistic.

Positives

• Inspire Medical Systems reports strong preliminary revenue performance for Q4 2024 and full-year 2024.
• The company is experiencing significant momentum with the expansion of medical centers and sales territories.
• The launch of the Inspire V neurostimulator is underway.
• A new organizational structure is being implemented to drive continued growth.
• The company is expanding its leadership team with the hiring of a new Chief Manufacturing and Quality Officer.
• The company has >90,000 patients treated, >$800M revenue, and >1,500 implanters.

Negatives

• Dr. Charisse Sparks, Chief Medical Officer, left Inspire at the beginning of the year.

Risks

• The preliminary revenue results are estimates and subject to revision.
• The company faces risks and uncertainties that could cause actual results to differ materially from forward-looking statements, including market acceptance, competition, and regulatory approvals.
• The company mentions the impact of glucagon-like peptide 1 class of drugs on demand for Inspire therapy as a risk.

Future Outlook

The company anticipates revenue for full year 2025 to be in the range of $940 million to $955 million, a 17% to 19% increase over full year 2024. The company is focused on continued growth and therapy adoption.

Management Comments

• We are very pleased with our strong preliminary revenue performance in the fourth quarter as the team executed exceptionally well and finished the year with significant momentum, said Tim Herbert, Chairman and Chief Executive Officer of Inspire Medical Systems.
• We are also excited to announce the first implants of the new Inspire V neurostimulation system, and a new organizational structure intended to further fuel our continued growth, including the expansion of our leadership team with the hiring of a new Chief Manufacturing and Quality Officer.
• The addition of our new Chief Manufacturing and Quality Officer along with the focused direction of our senior leadership team places the Company in a strong position to continue the growth in therapy adoption of Inspire therapy and to deliver strong value to all of our stakeholders, concluded Mr. Herbert.

Industry Context

Inspire Medical Systems operates in the medical technology industry, specifically focusing on solutions for obstructive sleep apnea. The company competes with traditional treatments like CPAP and surgical alternatives. The announcement highlights the company's growth and innovation in this space.

Comparison to Industry Standards

• The company's growth rate of 25% for the fourth quarter and 28% for the full year 2024 is strong compared to other medical device companies.
• The company's revenue guidance for 2025 indicates continued growth and market penetration.
• The company's focus on innovation, such as the Inspire V neurostimulator, positions it as a leader in the sleep apnea treatment market.
• Competitors in the sleep apnea market include ResMed and Philips, which offer CPAP devices and other respiratory solutions.

Management Changes

Stakeholder Impact

• Shareholders: The strong financial results and positive outlook are likely to be viewed favorably by shareholders.
• Employees: The new organizational structure and leadership changes may impact employees, but the company emphasizes a focus on employee health, well-being, and engagement.
• Customers: The launch of Inspire V and continued innovation are expected to benefit patients with obstructive sleep apnea.
• Suppliers: The company's growth may lead to increased demand for supplies and services from its third-party suppliers.
• Patients: Inspire patients experience a significant reduction in the severity of their OSA.

Next Steps

• Full launch of Inspire V in 2025.
• Continued investment in top-line growth and profitability.
• Further development and commercialization of innovative solutions for obstructive sleep apnea.

Key Dates